For breast cancer, PDPN+-CAFs tended to result in a more malignant pathological status and could facilitate immunosuppression and disease progression, which is consistent with the finding of this meta-analysis study and the findings of PDPN functions in multiple types of solid tumors (Du et al., 2023; Yamaguchi et al., 2021). This evidence concerns the gene PDPN and breast carcinoma.